AXL and neoplasm: Indeed, even though bemcentinib treatment consistently separates from DMSO vehicle control in our co-culture data, within the bemcentinib treatment the conditions remain separate based on tumor cell state, further supporting the hypothesis that the immune cell response to Axl inhibition is impacted by the perturbed tumor state that results from prior treatment with other therapeutics.